Listing - December 29, 2020
LIDDS to apply for listing on Nasdaq Stockholm Main Market
A listing on Nasdaq Stockholm Main Market is a natural next step in the company’s development, it states. “A move to Nasdaq Stockholm’s main market can contribute to increased interest from a broader investor base while at the same time increase the visibility and exposure of LIDDS, in Sweden and globally,” says Monica Wallter, CEO, […]
Listing - November 23, 2020
Pila Pharma announces plans to go public
The Swedish biotech company Pila Pharma has announced the decision to list the company. The Initial Public Offering (IPO), aiming for listing of the company’s shares on one of the unregulated stock exchanges in Sweden, is targeted for Q2-2021. To facilitate the IPO process, Göteborg Corporate Finance (GCF) has been selected as the capital finance […]
Listing - September 21, 2020
Implantica’s offering attracted strong interest
Implantica, a medtech group with operations within the implantable medical device and eHealth markets, announces the outcome of the offering in connection with the company’s listing on Nasdaq First North Premier Growth Market. The offering, including the Overallotment Option, consists of 19,461,537 Swedish Depository Receipts (“SDRs”), representing newly issued class A shares in Implantica (the […]
Listing - September 10, 2020
AstraZeneca to list US ADR equity and all US debt securities on Nasdaq
AstraZeneca has announced that it will be transferring the listing of its American Depositary Receipts (ADRs) and its US listed debt securities from the New York Stock Exchange (NYSE) to the Nasdaq Global Select Market (Nasdaq) and Nasdaq Bond Exchange respectively. The transfers will be effective after market close on Thursday 24 September 2020. AstraZeneca […]
Listing - March 26, 2020
Xspray moves to the main Nasdaq market
The first day of trading on Nasdaq Stockholm’s main market is 27 March 2020. March 18, 2020 that Nasdaq Stockholm’s listing committee had approved that the company’s shares are admitted to trading on Nasdaq Stockholm’s main market. On 23 March, the prospectus that has been prepared by the company in connection with the listing was […]
Listing - January 9, 2020
Herantis Pharma has completed an upsized directed share issue and listing on the Swedish First North Growth Market
This dual listing will further enable the advance its two innovative programs: CDNF in Parkinson’s Disease and drug candidate, Lymfactin, in Lymphedema. As part of the offering Herantis issued a total of 618,018 new shares at a price of €6.72 EUR / SEK 71 per share bringing the total number of shares in the Company […]
